One of the most important questions in #healthcare #AI is no longer whether a model performs well in isolation. It is whether the surrounding system is mature enough to make that performance usable, governable, and valuable in practice. That is particularly true in #cancer diagnostics, where the real challenge is not only interpretation, but the architecture around it: data quality, workflow integration, clinical trust, deployment discipline, and institutional readiness. This recent piece from Kinda Chebib reflects that broader shift in the market.
The next battleground in healthcare AI is not model accuracy. It is who controls the system around the model. Cancer diagnostic AI in Europe and MENA is shifting from algorithm competition to architecture competition: from “who has the best model?” to “who owns the deployment stack?” - Can it plug into real workflows? - Can it survive EU-level governance? - Can it scale from pilots to system capacity? In cancer imaging, durable value now sits in patient context, multimodal data, infrastructure, workflow integration, and governance - not in image interpretation alone. AIMG’s latest thought leadership from its Advisory Board on cancer diagnostic AI illustrates this shift and shows why expert-in-the-loop research matters. AIMG’s methodology combines quantitative evidence with practitioner insight from its Advisory Board and Expert Network to generate practitioner-level market and deployment insights, not just generic AI narratives. Europe is becoming the lab for trusted, regulated AI infrastructure. MENA brings demand growth and modernization pressure to redesign diagnostic pathways. The winners will not simply be the most accurate. They will be those who turn AI into trusted, reusable, investment-ready diagnostic infrastructure. Read the full AIMG Advisory Board insight here: From patient edge to imaging AI infrastructure: the new control points in cancer diagnostic AI across Europe and MENA: https://lnkd.in/ex4BU3N6